Abstract Library

#937 Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors

Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Panzuto F, Rinzivillo M, Fazio N, De Braud F, Luppi G,

Keywords: Everolimus, compassionate use,

#490 Effect of Open-Label Everolimus After Disease Progression in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis

Introduction: In the RADIANT-2 study (NCT00412061), Everolimus + Octreotide LAR (E+O) resulted in a clinically meaningful increase in median progression-free survival (PFS; by adjudicated central review) of 5.1 months v. placebo + Octreotide LAR (P+O) in patients with advanced NET with a history of carcinoid syndrome. Investigator-assessed PFS was 12.0 months for E+O compared with 8.6 months for P+O, respectively. On radiologically confirmed disease progression, P+O patients could cross over to open-label E+O.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Hörsch D, Luppi G, Jehl V, Peeters M, Hainsworth J,

Keywords: Everolimus, Octreotide LAR, somatostatin analog, mTOR,